Mutation analysis of the SLX4/FANCP gene in hereditary breast cancer

Mutation analysis of the SLX4/FANCP gene in hereditary breast cancer

  • نوع فایل : کتاب
  • زبان : انگلیسی
  • مؤلف : Rosa Landwehr Natalia V. Bogdanova Natalia Antonenkova Andreas Meyer Michael Bremer Tjoung-Won Park-Simon Peter Hillemanns Johann H. Kar
  • چاپ و سال / کشور: 2011

Description

SLX4 coordinates three structure-specific endonucleases in the DNA damage response. One subtype of Fanconi anaemia, FA-P, has recently been attributed to biallelic SLX4 gene mutations. To investigate whether monoallelic SLX4 gene defects play some role in the inherited component of breast cancer susceptibility, in this study we resequenced the whole SLX4 coding region and flanking untranslated sections in genomic DNA samples obtained from a total of 52 German or Byelorussian patients with familial breast cancer. Selected variants were subsequently screened by RFLP or TaqMan-based assays in an extended set of 965 German breast cancer cases and 985 healthy female controls. The resequencing study uncovered four new SLX4 missense substitutions, each of them in a single breast cancer patient. Three missense substitutions (p.V197A, p.G700R and p.R1034H) were not found in a subsequent screening of 240 additional breast cancer patients, while one missense substitution (p.R237Q) was more common and was detected in a total of 12 cases (1.3%) and seven controls (0.7%) in the Hannover breast cancer study. The rare missense substitution, p.G700R, resides in the conserved BTB domain and was in silico predicted to be pathogenic. Seven additional missense polymorphisms were correlated and formed one haplotype which was, however, neither associated with breast cancer risk nor with survival from breast cancer. In summary, this study did not reveal truncating or clearly pathogenic mutations, but unravelled four new unclassified missense variants at a low frequency. We conclude that there is no evidence for a major role of SLX4 coding variants in the inherited susceptibility towards breast cancer in German and Byelorussian patients, although very rare mutations such as the p.G700R substitution could make a minor contribution.
Breast Cancer Res Treat DOI 10.1007/s10549-011-1681-1 Received: 8 July 2011 / Accepted: 9 July 2011
اگر شما نسبت به این اثر یا عنوان محق هستید، لطفا از طریق "بخش تماس با ما" با ما تماس بگیرید و برای اطلاعات بیشتر، صفحه قوانین و مقررات را مطالعه نمایید.

دیدگاه کاربران


لطفا در این قسمت فقط نظر شخصی در مورد این عنوان را وارد نمایید و در صورتیکه مشکلی با دانلود یا استفاده از این فایل دارید در صفحه کاربری تیکت ثبت کنید.

بارگزاری